EDGAR·FLOW

MapLight Therapeutics, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
MapLight Therapeutics reported positive Phase 2 ZEPHYR trial results for ML-007C-MA (210/3 mg BID) in schizophrenia, meeting its primary endpoint with PANSS total score reduction of 4.5 points vs. placebo (effect size 0.37, p=0.015; 0.50 in completers). The company raised $150M in August 2026 and ended Q3 2026 with $463.4M cash, sufficient to fund operations through 2028, including planned Phase 3 ZEPHYR-2 trial (topline 2H 2027) and ongoing Phase 2 VISTA trial in Alzheimer's disease psychosis (topline 2028). ML-007C-MA also showed prespecified cognitive benefit (effect size 0.51, p=0.041) and was well-tolerated with 99% reaching target dose and low GI discontinuations (2%), contrasting favorably with Cobenfy's safety profile.
Why this rating

Successful Phase 2 de-risks registrational path; $463M cash runway (125% of company size) funds pivotal trials; cognitive signal differentiates competitor landscape meaningfully.

Tradability signal
NO TRADE

No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$7.14
+10 min · unknown
$7.14 ▲ 0.00%
+30 min · unknown
$6.96 ▼ 2.45%
+1 hr · unknown
$7.19 ▲ 0.70%
+4 hrs · unknown
$6.94 ▼ 2.80%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ MPLT · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.